Q-omics provides the consensus-scored SLC30A3 profile across patient tissues and cancer cell-line models. SLC30A3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SLC30A3 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, SLC30A3 RNA expression shows 17,267 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, HNSC, and GBM as cancer lineages where SLC30A3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC30A3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC30A3 survival associations across molecular data types. SLC30A3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC30A3 RNA expression–survival associations across cancer types. High SLC30A3 expression shows unfavorable associations in MESO, KIRP, COAD, BLCA and KIRC, but favorable associations in SCLC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SLC30A3 RNA expression.
This table summarizes SLC30A3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC30A3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC30A3 shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, THCA, LUSC and BLCA. The HNSC box plot shows higher SLC30A3 RNA expression in tumor versus normal tissue (log2 FC = +0.285, t-test p < 0.001).
This table shows molecular features associated with SLC30A3 in patient tissues and cancer cell lines. In patient samples, SLC30A3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC30A3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
